Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). - Wikidata - wikimedia - TriplyDB

Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

http://www.wikidata.org/entity/Q35532063

about

INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist Can biomarkers help to diagnose early heart failure with preserved ejection fraction?Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator Can Brain Natriuretic Peptides and Osteoprotegerin Serve As Biochemical Markers for the Detection of Aortic Pathology in Children and Adolescents with Turner Syndrome?High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study Sleep apnea and cognitive function in heart failure.N-terminal pro-brain natriuretic peptide levels and aortic diameters.Biochemical markers of aging for longitudinal studies in humans.Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.Heart failure in elderly: progress in clinical evaluation and therapeutic approach.N-terminal pro-B-type natriuretic peptide level inversely associates with metabolic syndrome in elderly persons.The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis.Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry.B-type natriuretic peptide and severity of cognitive disorder.A rapid and cost-effective method of producing recombinant proBNP and NT-proBNP variants in Escherichia coli for immunoassay of heart failure.Clinical signs, diagnostics and successful treatment of a myocarditis in an adult chimpanzee (Pan troglodytes).N-Terminal Pro-Brain Natriuretic Peptide Concentrations After Hypertensive Intracerebral Hemorrhage.N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy.Value of N-terminal pro brain natriuretic peptide levels in different types of Fontan circulation.Prediction of sudden death in elderly patients with heart failure.Establishment of normal reference values of NT-proBNP and its application in diagnosing acute heart failure in children with severe hand food and mouth disease

P2860

Q28083473-87B7DDDF-8AC9-4575-BFD2-C5A7123063B3 Q28087822-2FE9BD95-4C3C-4C6C-8C61-21B6A5E430C4 Q33671233-5C726AA4-4241-4FB7-878A-292E4EA7C112 Q33867461-AF263B4D-D5C9-485C-9C63-317B828F9D02 Q35228547-8453D83A-8EF9-4977-9952-9B2199D9882E Q35718016-E44D8144-0EB2-4C1C-8199-A0C10FDCC265 Q36055756-9077C690-DF8E-4E83-A48B-FF7B74A435F1 Q36254265-C8133513-2E6C-450B-9564-0ED8B3A8AA0A Q36449881-4442C455-0161-4426-B49A-108D150F7926 Q36541403-50A13436-C388-4499-96DE-CD82A23F7C67 Q36569151-BCBF3FC5-7CC9-4E73-A68B-E3DD3FD92A1A Q37001576-39633DFE-735C-46E2-B51D-58A221A3D31D Q37583858-2FBC0ACD-6E04-49EA-A89F-A09EB70C1346 Q37662756-AEFBA25F-11F0-4FE1-9D5B-EFA4D57E1709 Q38873927-099FAF23-8A20-41CC-A00B-AB7DE61D4E53 Q40584596-58D8DEF7-38FA-4168-B033-8F151C963EF3 Q41140893-4B8A98C1-3BDA-45FC-BF17-EB405BA87BA8 Q41364708-A0E672AE-6939-4A20-962D-020288662DB6 Q44120239-698F2D35-336B-4E06-A0E8-72319D0B11D1 Q44683095-0063255B-BCA7-48C8-8F1E-52C19B0E683B Q46363646-9CDDDDA6-EDE4-4758-A7B8-6A79B7C0A11C Q48376089-E8AD4BDF-5875-4974-B74C-2AD88836EF58 Q48411276-DB708518-C8D2-407B-A514-F05CA35D8E5B Q48930338-7E410C57-7909-4A5E-BE10-C5E479134871 Q51050516-0C731B8B-DDEA-4C3D-BC49-A7C85DB018E4 Q52584402-20CB679D-7DF7-4C43-9018-C6C3C9B21339 Q58759286-01D1C970-3DD1-43C4-BEBA-F23E48276A2F

P2860

Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

http://www.wikidata.org/entity/Q35532063

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reference limits for N-termina ...... m the Framingham Heart Study).

@ast

Reference limits for N-termina ...... m the Framingham Heart Study).

@en

type

label

Reference limits for N-termina ...... m the Framingham Heart Study).

@ast

Reference limits for N-termina ...... m the Framingham Heart Study).

@en

prefLabel

Reference limits for N-termina ...... m the Framingham Heart Study).

@ast

Reference limits for N-termina ...... m the Framingham Heart Study).

@en

P1433

Q35532063-CB5A5CD2-4A5E-4001-92F9-3CD628E43274

P1476

Q35532063-CE541838-163D-4FC8-B8BE-AB1978162A62

P2093

Q35532063-398FF520-FEE6-4047-8EF1-BA7F2D84F6ED

Q35532063-53BC4255-5AE7-4789-A771-BF6F83B0C8FF

Q35532063-7F220CEA-B7E4-463E-AB1C-E02E5A30C961

Q35532063-81C9BFFF-2BC9-473E-8A44-838A97324A92

Q35532063-88E78E30-DDCF-4632-8504-6F8584C5FEB0

Q35532063-9DDED270-50CD-4F2B-8003-AA783EFFF8D0

Q35532063-DF672104-C5E3-44CE-957F-D4C2179F6948

P2860

Q35532063-01484E10-9EDE-41F0-97A1-A2DCDAB73E3B

Q35532063-20EE3F46-27B2-4C5A-A9F7-F4FF95BC5540

Q35532063-28765734-2120-421E-8E83-4813D57DC5C7

Q35532063-2E4A55FC-87CF-44EE-B845-C1825C1444E0

Q35532063-2EED1BD3-22FC-4BF1-84B0-A1B5AE4DB0AA

Q35532063-2F9FF95D-FB94-4BD7-BA47-0BA1C2948B9A

Q35532063-3114E62A-FDC1-49A7-9416-915BE91ED5A7

Q35532063-320F0894-6B86-42E3-9219-347F107CAB93

Q35532063-59B22C6D-0DBE-4206-B224-019249274C20

Q35532063-7144B3AF-87FF-4F42-B11C-F65FCA512AD6

P304

Q35532063-C48A97D0-0160-4FB6-8818-172FFB2B5DBC

P31

Q35532063-77F4D046-1032-4CFB-8D3E-4FADC989FBBB

P356

Q35532063-D07ABE84-98F1-4D78-95BC-44BB4A09151E

P407

Q35532063-56FABE4C-B537-4098-8FF7-2B4B39DC897B

P433

Q35532063-506F714B-20C0-45A5-9927-6D5E999CD4A9

P478

Q35532063-A448D8E9-E329-4933-BCD6-A1A56761D1B0

P50

Q35532063-2F751F9B-7A11-47C9-A255-667D27F04D09

Q35532063-58B15C16-A3BE-422C-B96D-7F627FF2541F

P577

Q35532063-FF4B39AF-BFD6-4F5F-B72B-1CFBFC2DD6DF

P5875

Q35532063-CA11B199-B190-44AE-8918-A4C6EA5BA4CB

P698

Q35532063-91A52A08-4A87-4857-875B-462CF3B770D3

P932

Q35532063-79B362F9-435A-4F2B-BD26-6BAE6BE0CAD3

P356

J.AMJCARD.2011.06.057

P1433

American Journal of Cardiology

P1476

Reference limits for N-termina ...... m the Framingham Heart Study).

@en

P2093

Daniel Levy

http://www.w3.org/2001/XMLSchema#string

Elizabeth McCabe

http://www.w3.org/2001/XMLSchema#string

Erin Coglianese

http://www.w3.org/2001/XMLSchema#string

Michael G Fradley

http://www.w3.org/2001/XMLSchema#string

Ravi V Shah

http://www.w3.org/2001/XMLSchema#string

Susan Cheng

http://www.w3.org/2001/XMLSchema#string

Thomas J Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Plasma brain natriuretic peptide concentration: impact of age and gender.

Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly.

Pediatric brain natriuretic peptide concentrations vary with age and sex and appear to be modulated by testosterone.

Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging.

Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.

Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): a study in blood donors.

Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

P304

1341-1345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJCARD.2011.06.057

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Ramachandran S. Vasan

Martin G Larson

P577

2011-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51593206

http://www.w3.org/2001/XMLSchema#string

P698

21864812

http://www.w3.org/2001/XMLSchema#string

P932

3209520

http://www.w3.org/2001/XMLSchema#string